EpiVario Awarded NIH Grant to Advance Research in Treatments for Cocaine Use Disorder
Summary
Despite these figures, there are no FDA-approved pharmacological treatments for CUD.EpiVario has discovered an epigenetic approach to treating CUD by regulating neuronal plasticity to attenuate unwanted cocaine-related learning. Positive results from this study will allow the company to move forward with its plans to file an Investigative New Drug (IND) application with the FDA. "This award marks a significant milestone for both our company and the millions affected by cocaine addiction worldwide," said Thomas Kim, President & CEO of EpiVario. By targeting this activity to modulate stress and drug-related memories, EpiVario is establishing a novel, differentiated, and promising approach to address substance use disorders and PTSD.For further information, please visit epivario.com. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article.